Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on an application for cetylated fatty acids as a novel food (NF) pursuant to Regulation (EU) 2015/2283. The NF concerns primarily a mixture of cetylated myristic acid and cetylated oleic acid synthesised from cetyl alcohol, myristic acid and oleic acid, and to a lesser degree, other cetylated fatty acids and other compounds from olive oil. The NF is intended for use in food supplements for the general adult population. The highest dose tested in a subchronic toxicity study in rats, i.e. 4,500 mg/kg per day, was considered to be the no-observed-adverse effect level. By applying the default uncertainty factor of 200 as suggested by the EFSA Scientific Committee (2012), and considering a default body weight of 70 kg for the adult target population, this would result in an intake of 1.6 g per day, which is lower than the maximum intake proposed by the applicant (i.e. 2.1 g per day). The Panel concludes that the NF, cetylated fatty acids, is safe at an intake of 1.6 g per day for the intended target population, i.e. adults.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8294049PMC
http://dx.doi.org/10.2903/j.efsa.2021.6670DOI Listing

Publication Analysis

Top Keywords

cetylated fatty
16
fatty acids
16
acids novel
8
novel food
8
food pursuant
8
pursuant regulation
8
regulation 2015/2283
8
myristic acid
8
oleic acid
8
target population
8

Similar Publications

Spent coffee grounds, the main by-product of the coffee-brewing process, were valorized as a renewable source of lipids for the synthesis of novel wax esters and as an alternative and sustainable oil-structuring agent for the production of oleogels. The lipase-catalyzed reactions were implemented using fatty alcohols both under solvent-free conditions and with limonene as an environmentally friendly solvent. Wax esters were evaluated for their ability to formulate olive oil oleogels through the determination of the physical properties of oleogels.

View Article and Find Full Text PDF

An effective approach to stabilize emulsions is to increase the rigidity of oil-water (O/W) interfacial films by adsorbing molecular assemblies such as lamellar phases around the emulsion particles. In this study, we aimed to analyze the structure of a lamellar phase adsorbed at an O/W interface and to clarify the effect of the structure and physicochemical properties of the lamellar phase on the dispersion stability of emulsions. The adsorption of the lamellar phase at the O/W interface of the emulsions was confirmed by freeze-fracture transmission electron microscopy of O/W emulsions prepared by diluting and dispersing gels formed with polyglycerol fatty acid esters, water, and cetyl isooctanoate (CIO).

View Article and Find Full Text PDF

The adsorbed film of Sodium Hexadecyl Sulfate (SHS) at the dodecane - water interface showed a first-order phase transition to a surface frozen monolayer upon cooling by the lateral van der Waals attraction between their hydrophobic tails and those of hexadecanol (C16OH) incorporated from the dodecane phase. The surface freezing transition of the SHS - C16OH monolayer was then utilized to stabilize an oil-in-water (OW) emulsion. The obtained results were compared to those examined previously for the cetyltrimethylammonium chloride (CTAC) - C16OH surface frozen monolayer.

View Article and Find Full Text PDF

Lacidipine (LCD) is a potent antihypertensive agent. Fatty-based nanovesicles (FNVs) were designed to improve LCD low solubility and bioavailability. LCD-FNVs were formulated according to different proportions of cetyl alcohol, cremophor®RH40, and oleic acid adopting Box-Behnken Design.

View Article and Find Full Text PDF

Objective/aim: This study aimed to assess how effective an oral form of Cetylated fatty acids compounds (CFA) is in improving the physical function, pain, and stiffness of individuals suffering from knee osteoarthritis (OA) and how its effectiveness compares to that of Meloxicam, a non-steroidal anti-inflammatory drug (NSAID).

Methods: For this parallel-arm randomised clinical trial, 48 adult patients with knee OA were divided into two groups. The intervention group was prescribed 350mg CFA capsule three times per day for 30 days.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!